State ID: ______________ **Date of Incident Specimen Collection (*mm-dd-yyyy*):** ___-___-_______ **Surveillance Officer Initials** _________

Form Approved
OMB No. 0920-0978

CANDIDEMIA 2024 CASE REPORT FORM

Patient name: ____ (Last, First, MI)

Medical Record No.: ____________________________________

Address: ____ (Number, Street, Apt. No.)

_____________________________ (City, State) _________________ (Zip Code)

Hospital: ____

Acc No. (incident isolate): ______________________________

Acc No. (subseq isolate): ______________________________

Address type:
1 ☐Residential 2 ☐Post office 3 ☐Long-term care facility 4 ☐Corrections 5 ☐Military 6 ☐Homeless 7 ☐Other 8 ☐Insufficient 9 ☐Missing

Phone no.: (   ) _________ - ________________________

Check if not a case: ☐

Reason not a case: ☐Out of catchment area ☐Duplicate entry ☐Not candidemia ☐Unable to verify address ☐Other (specify):_____________

SURVEILLANCE OFFICER INFORMATION

1. Date reported to EIP site: ___ ___ - ___ ___ - ___ ___ ___ ___

2. Date review completed: ___ ___ - ___ ___ - ___ ___ ___ ___

3. Was case first identified through audit? 1 ☐Yes 0 ☐No

4. Isolate available? 1 ☐Yes 0 ☐No

5. Previous candidemia episode? 1 ☐Yes 0 ☐No 9 ☐Unknown

5a. If yes, enter state IDs: ☐☐☐☐☐☐☐☐ ☐☐☐☐☐☐☐☐ ☐☐☐☐☐☐☐☐

6. CRF status: 1 ☐Complete 2 ☐Pending 3 ☐Chart unavailable

7. SO's initials: _________

DEMOGRAPHICS

8. State ID: ☐☐☐☐☐☐☐☐ **10. State:** __________________ **11. County:** ________________________

9. Patient ID: _____________________________

12. Lab ID where positive culture was identified: __________________

13. Date of birth (*mm-dd-yyyy*)**:** ___ ___ - ___ ___ - ___ ___ ___ ___

14. Age: __________ 1 ☐days 2 ☐mos 3 ☐yrs

15. Sex: ☐Male ☐Female ☐Check if transgender

16. Weight: __________ **lbs.** _________ **oz. OR** __________**kg** ☐ Unknown

17. Height: __________ **ft.** _________ **in. OR** __________**cm** ☐ Unknown

18. BMI: (record only if ht. and/or wt. is not available) ___________________ ☐ Unknown

19. Race *(check all that apply):*
☐American Indian/Alaska Native ☐Native Hawaiian/Pacific Islander
☐Asian ☐White
☐Black/African American ☐Unknown

20. Ethnic origin:
1 ☐Hispanic/Latino
2 ☐Not Hispanic/Latino
9 ☐Unknown

LABORATORY DATA

21. Date of Incident Specimen Collection (DISC) (*mm-dd-yyyy*): ___ ___ - ___ ___ - ___ ___ ___ ___

22. Location of Specimen Collection:

☐Hospital Inpatient
Facility ID: _________
☐ ICU
☐ Surgery/OR
☐ Radiology
☐ Other inpatient

☐ Outpatient
Facility ID: _________
☐ Emergency Room
☐ Clinic/Doctor's office
☐ Dialysis center
☐ Surgery
☐ Observational/clinical decision unit
☐ Other outpatient

☐ LTCF
Facility ID: _________
☐ LTACH
Facility ID: _________
☐ Autopsy
☐ Other (specify): ________________________
☐ Unknown

23. *Candida* species from initial positive blood culture *(check all that apply):*

☐*Candida albicans* (CA)
☐*Candida auris* (CAU)
☐*Candida glabrata* (CG)
☐*Candida parapsilosis* (CP)
☐*Candida tropicalis* (CT)
☐*Candida dubliniensis* (CD)
☐*Candida lusitaniae* (CL)
☐*Candida krusei* (CK)
☐*Candida guilliermondii* (CGM)
☐*Candida*, other (CO) specify: ______________
☐*Candida*, germ tube negative/non albicans (CGN)
☐*Candida* species (CS)
☐Pending

Public reporting burden of this collection of information is estimated to average 40 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road NE, MS D-74, Atlanta, Georgia 30329; ATTN: PRA (0920-0978).

24. Antifungal susceptibility testing (check here ☐ if no testing done/no test reports available):

Date of culture	Species	Drug	MIC	Interpretation
	1 ☐CA 13 ☐CAU 2 ☐CG 3 ☐CP 4 ☐CT 5 ☐CD 6 ☐CL 7 ☐CK 8 ☐CGM 9 ☐CO 10 ☐CGN 11 ☐CS 12 ☐Pending	Amphotericin B		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Anidulafungin (Eraxis)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Caspofungin (Cancidas)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Fluconazole (Diflucan)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Flucytosine (5FC)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Itraconazole (Sporanox)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Micafungin (Mycamine)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Posaconazole (Noxafil)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Voriconazole (Vfend)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
	1 ☐CA 13 ☐CAU 2 ☐CG 3 ☐CP 4 ☐CT 5 ☐CD 6 ☐CL 7 ☐CK 8 ☐CGM 9 ☐CO 10 ☐CGN 11 ☐CS 12 ☐Pending	Amphotericin B		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Anidulafungin (Eraxis)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Caspofungin (Cancidas)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Fluconazole (Diflucan)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Flucytosine (5FC)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Itraconazole (Sporanox)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Micafungin (Mycamine)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Posaconazole (Noxafil)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Voriconazole (Vfend)		☐S ☐SDD ☐I ☐R ☐NI ☐ND

25. Did the patient have a PCR molecular test for *Candida* (e.g., T2), in the 6 days before or two days after the DISC?

1 ☐Yes 0 ☐No 9 ☐Unknown

25a. If yes, test type: ______________________

25b. Result: ______________________________

26. Any subsequent positive *Candida* blood cultures in the 29 days after, not including the DISC? 1 ☐Yes 0 ☐No 9 ☐Unknown

26a. If yes, provide dates of all subsequent positive *Candida* blood cultures and select the species:

Date Drawn (*mm-dd-yyyy*)	**Species identified***
___ ___ - ___ ___ - ___ ___ ___ ___	☐CA ☐CAU ☐CG ☐CP ☐CT ☐CD ☐CL ☐CK ☐CGM ☐CO:_________ ☐CGN ☐CS ☐Pending
___ ___ - ___ ___ - ___ ___ ___ ___	☐CA ☐CAU ☐CG ☐CP ☐CT ☐CD ☐CL ☐CK ☐CGM ☐CO:_________ ☐CGN ☐CS ☐Pending
___ ___ - ___ ___ - ___ ___ ___ ___	☐CA ☐CAU ☐CG ☐CP ☐CT ☐CD ☐CL ☐CK ☐CGM ☐CO:_________ ☐CGN ☐CS ☐Pending
___ ___ - ___ ___ - ___ ___ ___ ___	☐CA ☐CAU ☐CG ☐CP ☐CT ☐CD ☐CL ☐CK ☐CGM ☐CO:_________ ☐CGN ☐CS ☐Pending

***Attach additional MIC page if additional *Candida* species (different from original), if another *C. glabrata* (even if original was *C. glabrata*), or if same *Candida* species (if no AFST results available for original)**

27. Documented negative *Candida* blood culture on the day of or in the 29 days after the DISC (in which no blood cultures after this negative culture were positive in the 29 days after the DISC)? 1 ☐Yes 0 ☐No 9 ☐Unknown

27a. If yes, date of negative blood culture: ___ ___ - ___ ___ - ___ ___ ___ ___

28. On the day of or in the 6 days before the DISC, was the patient known to be colonized with or being managed as if they were colonized with a multi-drug resistant organism (MDRO) (e.g., on contact precautions)? MDROs include CRE, CRPA, CRAB, MRSA, and VRE.

1 ☐Yes 0 ☐No 9 ☐Unknown

28a. If yes, specify organisms *(Enter up to 3 pathogens)*: __________________, __________________, __________________

29. Additional non-*Candida* organisms isolated from blood cultures on the day of or in the 6 days before the DISC:

1 ☐Yes 0 ☐No 9 ☐Unknown

29a. If yes, additional organisms (*Enter up to 3 pathogens*): __________________, __________________, __________________

30. Did the patient have any of the following types of infection related to their *Candida* infection? *(check all that apply):*

☐None ☐Unknown

☐Abdominal infection
- ☐Hepatobiliary or pancreatic
- ☐Abscess (specify): _________
- ☐Peritonitis/peritoneal fluid
- ☐Splenic

☐Urinary tract infection

☐Esophagitis

☐Oral/thrush

☐Osteomyelitis

☐Skin /wound infection

☐Pulmonary infection
- ☐Abscess

☐CNS infection (meningitis, brain abscess)

☐Eyes
- ☐ Endophthalmitis
- ☐ Chorioretinitis

☐Endocarditis
- ☐Septic emboli (specify location): ________

☐Other (specify): __________

MEDICAL ENCOUNTERS

31. Was the patient hospitalized on the day of or in the 6 days after the DISC? 1 ☐Yes 0 ☐No 9 ☐Unknown

31a. If yes,

Date of first admission: ___ ___ - ___ ___ - ___ ___ ___ ___ ☐Unknown

Hospital ID: ____________________ ☐Unknown

31b. Was the patient transferred during this hospitalization?

1 ☐Yes 0 ☐No 9 ☐Unknown

If yes, enter up to two transfers:

Date of transfer: ___ ___ - ___ ___ - ___ ___ ___ ___ ☐ Unknown

Hospital ID: ____________________ ☐Unknown

Date of second transfer: ___ ___ - ___ ___ - ___ ___ ___ ___ ☐ Unknown

Hospital ID: ____________________ ☐Unknown

31c. Where was the patient located prior to admission or, if not currently hospitalized, where was the patient located on the 3rd calendar day before the DISC? (*Check one*)

1 ☐Private residence

2 ☐Hospital inpatient
Facility ID: ___________

3 ☐LTCF
Facility ID: ___________

4 ☐LTACH
Facility ID: ____________

5 ☐Homeless

6 ☐Incarcerated

7 ☐Other (specify): ____________________

9 ☐Unknown

32. Was the patient in an ICU in the 14 days before, not including the DISC?

1 ☐Yes 0 ☐No 9 ☐Unknown

33. Was the patient in an ICU on the day of incident specimen collection or in the 13 days after the DISC?

1 ☐Yes 0 ☐No 9 ☐Unknown

34. Did the patient receive dialysis or renal replacement therapy (RRT) in the 30 days before the DISC, not including the DISC?

1 ☐Yes 0 ☐No 9 ☐Unknown

35. Patient outcome: 1 ☐Survived 9 ☐Unknown 2 ☐Died

Date of discharge:

___ ___ - ___ ___ - ___ ___ ___ ___ ☐Unknown

☐ Left against medical advice (AMA)

Date of death:

___ ___ - ___ ___ - ___ ___ ___ ___ ☐Unknown

35a. Discharged to:

0 ☐Not applicable (i.e. patient died, or not hospitalized)
1 ☐Private residence
2 ☐LTCF Facility ID: _______________
3 ☐LTACH Facility ID: _______________
5 ☐Other (specify): __________________
6 ☐Homeless
7 ☐Incarcerated
9 ☐ Unknown

36. Did the patient have any of the following classes or specific ICD-10 codes, including any sub-codes for this hospitalization?
(*Check all that apply):* ☐None ☐Unknown ☐Not applicable (i.e., patient not hospitalized)

☐ B37 (candidiasis)
Specify sub-code: _________________
Specify sub-code: _________________
☐ P37.5 (neonatal candidiasis)
☐ B48 (other mycoses, not classified elsewhere)
☐ B49 (unspecified mycoses)
☐ T80.211 (BSI due to central venous catheter)
☐ A41.9 (sepsis, unspecified organism)
☐ R65.2 (severe sepsis)
☐ Other *Candida*-related code
Specify code: _________________

37. Previous Hospitalization in the <u>90 days before</u>, not including the DISC: 1 ☐Yes 0 ☐No 9 ☐Unknown
37a. If yes, date of discharge: ___ ___ - ___ ___ - ___ ___ ___ ___ ☐Unknown
Facility ID: ___________

38. Overnight stay in LTACH in the <u>90 days before</u>, not including the DISC: 1 ☐Yes 0 ☐No 9 ☐Unknown
Facility ID: ___________

39. Overnight stay in LTCF in the <u>90 days before</u>, not including the DISC: 1 ☐Yes 0 ☐No 9 ☐Unknown
Facility ID: ___________

UNDERLYING CONDITIONS

40. Underlying conditions (*Check all that apply*): ☐**None** ☐**Unknown**

☐**Chronic Lung Disease**
- ☐Cystic Fibrosis
- ☐Chronic Pulmonary disease

☐**Chronic Metabolic Disease**
- ☐Diabetes Mellitus
  - ☐With Chronic Complications

☐**Cardiovascular Disease**
- ☐CVA/Stroke/TIA
- ☐Congenital Heart disease
- ☐Congestive Heart Failure
- ☐Myocardial infarction
- ☐Peripheral Vascular Disease (PVD)

☐**Gastrointestinal Disease**
- ☐Diverticular disease
- ☐Inflammatory Bowel Disease
- ☐Peptic Ulcer Disease
- ☐Short gut syndrome

☐**Immunocompromised Condition**
- ☐ HIV infection
  - ☐AIDS/CD4 count <200
- ☐Primary Immunodeficiency
- ☐Transplant, Hematopoietic Stem Cell
- ☐Transplant, Solid Organ (specify): _______

☐**Liver Disease**
- ☐Chronic Liver Disease
  - ☐Ascites
  - ☐Cirrhosis
  - ☐Hepatic Encephalopathy
  - ☐Variceal Bleeding
  - ☐Hepatitis B, chronic
- ☐Hepatitis C
  - ☐Treated, in SVR
  - ☐Current, chronic
- ☐Hepatitis B, acute

☐**Malignancy**
- ☐Malignancy, Hematologic
- ☐Malignancy, Solid Organ (non-metastatic)
- ☐Malignancy, Solid Organ (metastatic)

☐**Neurologic Condition**
- ☐Cerebral palsy
- ☐Chronic Cognitive Deficit
- ☐Dementia
- ☐Epilepsy/seizure/seizure disorder
- ☐Multiple sclerosis
- ☐Neuropathy
- ☐Parkinson's disease
- ☐Other (specify): _______________

☐**Plegias/Paralysis**
- ☐Hemiplegia
- ☐Paraplegia
- ☐Quadriplegia

☐**Renal Disease**
- ☐Chronic Kidney Disease
  - Lowest serum creatinine: ____________mg/DL
  - ☐Unknown or not done

☐**Skin Condition**
- ☐Burn
- ☐Decubitus/Pressure Ulcer
- ☐Surgical Wound
- ☐Other chronic ulcer or chronic wound
- ☐Other (specify): _______________

☐**Other**
- ☐Connective tissue disease
- ☐Obesity or morbid obesity
- ☐Pregnant

State ID: ______________ Date of Incident Specimen Collection (*mm-dd-yyyy*): ___-___-_______ Surveillance Officer Initials ________

SOCIAL HISTORY

41. Smoking *(Check all that apply):*

☐None ☐Unknown

☐Tobacco ☐E-nicotine delivery system ☐Marijuana

42. Alcohol Abuse:

1 ☐Yes
0 ☐No
9 ☐Unknown

43. Other Substances *(Check all that apply):* ☐**None** ☐**Unknown**

Substance	Documented Use Disorder (DUD/Abuse):	Mode of Delivery *(Check all that apply):*
☐Marijuana (other than smoking)	☐DUD or abuse	☐IDU ☐Non-IDU ☐Unknown
☐Opioid, DEA schedule I (e.g., Heroin)	☐DUD or abuse	☐IDU ☐Non-IDU ☐Unknown
☐Opioid, DEA schedule II-IV (e.g., methadone, oxycodone)	☐DUD or abuse	☐IDU ☐Non-IDU ☐Unknown
☐Opioid, NOS	☐DUD or abuse	☐IDU ☐Non-IDU ☐Unknown
☐Cocaine	☐DUD or abuse	☐IDU ☐Non-IDU ☐Unknown
☐Methamphetamine	☐DUD or abuse	☐IDU ☐Non-IDU ☐Unknown
☐Other (specify): _________________	☐DUD or abuse	☐IDU ☐Non-IDU ☐Unknown
☐Unknown substance	☐DUD or abuse	☐IDU ☐Non-IDU ☐Unknown

44. During the current hospitalization, did the patient receive medication-assisted treatment (MAT) for opioid use disorder?

1 ☐Yes 0 ☐No 8 ☐N/A (patient not hospitalized or did not have DUD) 9 ☐Unknown

OTHER CONDITIONS

45. For cases ≤ 1 year of age: Gestational age at birth: _______ wks 9 ☐Unknown AND Birth weight: __________ gms 9 ☐Unknown

46. Chronic Dialysis: ☐ Not on chronic dialysis ☐ Unknown

Type: ☐ Hemodialysis ☐ Peritoneal

46a. If Hemodialysis, type of vascular access:

☐ AV fistula/graft ☐ Hemodialysis central line ☐ Unknown

47. Surgeries in the <u>90 days before,</u> not including the DISC:

☐Abdominal surgery (specify): _________________

If yes: 1 ☐Open abdomen 0 ☐Laparoscopic 9 ☐Unknown

☐Non-abdominal surgery (specify): __________________

☐No surgery

48. Pancreatitis in the <u>90 days before,</u> not including the DISC:

1 ☐Yes
0 ☐No
9 ☐Unknown

49. Did the patient have any ostomies of the gastrointestinal tract including ileostomy, colostomy, etc. in the 30 calendar days before, not including the DISC?

1 ☐Yes 0 ☐No 9 ☐Unknown

50. Chronic Urinary Tract Problems/Abnormalities:

1 ☐Yes 0 ☐No 9 ☐Unknown

50a. If yes, did the patient have any urinary tract procedures in the 90 days before, not including the DISC?

1 ☐Yes 0 ☐No 9 ☐Unknown

51. Was the patient neutropenic in the 2 calendar days before, not including the DISC?

1 ☐Yes 0 ☐No 9 ☐Unknown (no WBC days -2 or 0, or no differential)

52. Did the patient have a CVC in the 2 calendar days before, not including the DISC?

1 ☐Yes 2 ☐No 3 ☐Had CVC but can't find dates 9 ☐Unknown

If yes, was the central line in place for > 2 calendar days: 1 ☐Yes 0 ☐No 9 ☐Unknown

52a. If yes, CVC type: (*Check all that apply*)

☐Non-tunneled CVCs ☐Implantable ports ☐Other (specify): _________________________

☐Tunneled CVCs ☐Peripherally inserted central catheter (PICC) ☐Unknown

52b. Were <u>all</u> CVCs removed or changed in the 2 days before or in the 6 days after the DISC?

1 ☐Yes
2 ☐No
3 ☐CVC removed, but can't find dates
5 ☐Died or discharged before indwelling catheter replaced
9 ☐Unknown

53. Did the patient have a midline catheter in the 2 calendar days before, not including the DISC?

1 ☐Yes 0 ☐No 9 ☐Unknown

54. Did the patient have any of the following indwelling devices or other devices present in the 2 calendar days before, not including the DISC? ☐None ☐Unknown

☐Urinary Catheter/Device
- ☐Indwelling urethral
- ☐Suprapubic

☐Respiratory
- ☐ET/NT
- ☐Tracheostomy
- ☐Invasive mechanical ventilation

☐Gastrointestinal
- ☐Abdominal drain (specify): _________________
- ☐Gastrostomy

55. Did the patient have a positive SARS-CoV-2 test result (molecular assay, antigen, or other confirmatory test, excluding serology) from a specimen collected in the 90 days before the DISC or on the DISC?

1 ☐Yes 0 ☐No 9 ☐Unknown

55a. If yes, date of specimen collection for initial positive SARS-CoV-2 test:

Date: ________ 9 ☐ Date Unknown

55b. If yes, EIP COVID-NET Case ID: ____________ ☐ None or N/A

56. Did the patient receive systemic antibacterial medication in the 14 days before, not including the DISC?

1 ☐Yes 0 ☐No 9 ☐Unknown

57. Did the patient receive any systemic steroids in the 30 days before, not including the DISC?

1 ☐Yes 0 ☐No 9 ☐Unknown

57a. If yes, what was the reason steroids were administered? *(check all that apply)*

- ☐ Steroid(s) given as an outpatient medication
- ☐ Steroid(s) given, prior to *Candida* DISC, during hospitalization associated with candidemia episode
- ☐ Steroid(s) given as part of treatment/management for COVID-19
- ☐ None of the above

58. Did the patient receive total parenteral nutrition (TPN) in the 14 days before, not including the DISC?

1 ☐Yes 0 ☐No 9 ☐Unknown

59. Did the patient receive systemic antifungal medication on the day of or in the 13 days before the DISC?

1 ☐Yes *(if Yes, fill out question 66)* 0 ☐No 9 ☐Unknown

60. Was the patient administered systemic antifungal medication after, not including the DISC?

1 ☐Yes *(if Yes, fill out question 66)* 0 ☐No 9 ☐Unknown

61. If antifungal medication was not given to treat current candidemia infection, what was the reason?

1 ☐Patient died before culture result available to clinicians

2 ☐Comfort care only measures were instituted

3 ☐Patient discharged before culture result available to clinician

4 ☐Medical records indicated culture result not clinically significant or contaminated

5 ☐Other reason documented in medical records, specify: ______________

6 ☐Patient refused treatment against medical advice

9 ☐Unknown

------------IF ANY ANTIFUNGAL MEDICATION WAS GIVEN, COMPLETE NEXT PAGE. ------------

OTHER

62. Does the chart indicate that the incident specimen was considered a contaminant or was considered to not be indicative of true infection?

1 ☐Yes 0 ☐No 9 ☐Unknown

63. Was the patient under the care of an infectious disease physician on the day of the DISC or within the 6 days after the DISC?

1 ☐Yes 0 ☐No 9 ☐Unknown

64. Did the patient have an echocardiogram (ECHO), including transthoracic (TTE) or transesophogeal (TEE), on the day of or 13 days after the DISC?

1 ☐Yes 0 ☐No 9 ☐Unknown

65. Did the patient have a dilated fundoscopic eye exam on the day of or 13 days after the DISC?

1 ☐Yes 0 ☐No 9 ☐Unknown

ANTIFUNGAL MEDICATION TABLES

Drug abbreviations (**NOTE: Please use abbreviation when entering data**):

Amphotericin – any IV formulation (Amphotec, Amphocil, Fungizone, Abelcet, AmBiosome, etc.)=AMBIV
Anidulafungin (Eraxis)=ANF
Caspofungin (Cancidas)=CAS
Fluconazole (Diflucan)=FLC
Flucytosine (5FC)=5FC
Isavuconazole (cresemba)=ISU
Itraconazole (Sporanox)=ITC
Micafungin (Mycamine)=MFG
Other=OTH
Posaconazole (Noxafil)=PSC
UNKNOWN DRUG=UNK
Voriconazole (Vfend)=VRC

66. ANTIFUNGAL MEDICATION

a. Drug Abbrev	b. First date given (*mm-dd-yyyy*)	c. Date start unknown	d. Last date given (*mm-dd-yyyy*)	e. Date stop unknown	f. Indication	g. Reason for stopping (if applicable)*
	__ __ - __ __ - __ __ __ __	☐	__ __ - __ __ - __ __ __ __	☐	☐ Prophylaxis ☐ Treatment	
	__ __ - __ __ - __ __ __ __	☐	__ __ - __ __ - __ __ __ __	☐	☐ Prophylaxis ☐ Treatment	
	__ __ - __ __ - __ __ __ __	☐	__ __ - __ __ - __ __ __ __	☐	☐ Prophylaxis ☐ Treatment	
	__ __ - __ __ - __ __ __ __	☐	__ __ - __ __ - __ __ __ __	☐	☐ Prophylaxis ☐ Treatment	
	__ __ - __ __ - __ __ __ __	☐	__ __ - __ __ - __ __ __ __	☐	☐ Prophylaxis ☐ Treatment	
	__ __ - __ __ - __ __ __ __	☐	__ __ - __ __ - __ __ __ __	☐	☐ Prophylaxis ☐ Treatment	
	__ __ - __ __ - __ __ __ __	☐	__ __ - __ __ - __ __ __ __	☐	☐ Prophylaxis ☐ Treatment	
	__ __ - __ __ - __ __ __ __	☐	__ __ - __ __ - __ __ __ __	☐	☐ Prophylaxis ☐ Treatment	
	__ __ - __ __ - __ __ __ __	☐	__ __ - __ __ - __ __ __ __	☐	☐ Prophylaxis ☐ Treatment	
	__ __ - __ __ - __ __ __ __	☐	__ __ - __ __ - __ __ __ __	☐	☐ Prophylaxis ☐ Treatment	

*Reasons for stopping antifungal treatment include: (1) completion of treatment; (2) started on different antifungal; (3) hospital discharge; (4) withdrawal of care/transition to comfort care only; (5) death; (6) other; (7) no additional records/lost to follow-up; (8) not applicable, no therapy given; and (9) unknown.

------------------------------------END OF CHART REVIEW FORM------------------------------------

AFST results for additional *Candida* isolates

Antifungal susceptibility testing (check here ☐ if no testing done/no test reports available):

Date of culture	Species	Drug	MIC	Interpretation
	1 ☐CA 13 ☐CAU 2 ☐CG 3 ☐CP 4 ☐CT 5 ☐CD 6 ☐CL 7 ☐CK 8 ☐CGM 9 ☐CO 10 ☐CGN 11 ☐CS 12 ☐Pending	Amphotericin B		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Anidulafungin (Eraxis)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Caspofungin (Cancidas)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Fluconazole (Diflucan)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Flucytosine (5FC)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Itraconazole (Sporanox)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Micafungin (Mycamine)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Posaconazole (Noxafil)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Voriconazole (Vfend)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
	1 ☐CA 13 ☐CAU 2 ☐CG 3 ☐CP 4 ☐CT 5 ☐CD 6 ☐CL 7 ☐CK 8 ☐CGM 9 ☐CO 10 ☐CGN 11 ☐CS 12 ☐Pending	Amphotericin B		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Anidulafungin (Eraxis)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Caspofungin (Cancidas)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Fluconazole (Diflucan)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Flucytosine (5FC)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Itraconazole (Sporanox)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Micafungin (Mycamine)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Posaconazole (Noxafil)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Voriconazole (Vfend)		☐S ☐SDD ☐I ☐R ☐NI ☐ND

Antifungal susceptibility testing (check here ☐ if no testing done/no test reports available):

Date of culture	Species	Drug	MIC	Interpretation
	1 ☐CA 13 ☐CAU 2 ☐CG 3 ☐CP 4 ☐CT 5 ☐CD 6 ☐CL 7 ☐CK 8 ☐CGM 9 ☐CO 10 ☐CGN 11 ☐CS 12 ☐Pending	Amphotericin B		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Anidulafungin (Eraxis)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Caspofungin (Cancidas)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Fluconazole (Diflucan)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Flucytosine (5FC)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Itraconazole (Sporanox)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Micafungin (Mycamine)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Posaconazole (Noxafil)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Voriconazole (Vfend)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
	1 ☐CA 13 ☐CAU 2 ☐CG 3 ☐CP 4 ☐CT 5 ☐CD 6 ☐CL 7 ☐CK 8 ☐CGM 9 ☐CO	Amphotericin B		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Anidulafungin (Eraxis)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Caspofungin (Cancidas)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Fluconazole (Diflucan)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Flucytosine (5FC)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Itraconazole (Sporanox)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Micafungin (Mycamine)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
		Posaconazole (Noxafil)		☐S ☐SDD ☐I ☐R ☐NI ☐ND

	10 ☐CGN 11 ☐CS 12 ☐Pending	Voriconazole (Vfend)		☐S ☐SDD ☐I ☐R ☐NI ☐ND